P
BMY icon

&Partners’s Bristol-Myers Squibb BMY Stock Holding History

&Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.51M Buy
165,112
+3,539
+2% +$203K 0.04% 394
2026
Q1 		$9.79M Buy
161,573
+18,733
+13% +$1.09M 0.05% 331
2025
Q4 		$7.71M Buy
142,840
+15,701
+12% +$755K 0.04% 369
2025
Q3 		$5.73M Buy
127,139
+7,060
+6% +$330K 0.04% 388
2025
Q2 		$5.56M Sell
120,079
-23,686
-16% -$1.16M 0.04% 348
2025
Q1 		$8.63M Buy
143,765
+10,722
+8% +$625K 0.09% 211
2024
Q4 		$7.49M Buy
133,043
+40,301
+43% +$2.25M 0.09% 220
2024
Q3 		$4.82M Buy
92,742
+41,662
+82% +$1.95M 0.09% 208
2024
Q2 		$2.12M Buy
51,080
+33,469
+190% +$1.5M 0.09% 206
2024
Q1 		$955K Buy
17,611
+7,616
+76% +$388K 0.13% 159
2023
Q4 		$513K Buy
9,995
+2,652
+36% +$139K 0.13% 153
2023
Q3 		$426K Sell
7,343
-440
-6% -$27K 0.2% 95
2023
Q2 		$498K Sell
7,783
-550
-7% -$36.9K 0.22% 86
2023
Q1 		$578K Sell
8,333
-260
-3% -$18.3K 0.28% 68
2022
Q4 		$618K Sell
8,593
-40
-0.5% -$3.02K 0.31% 66
2022
Q3 		$614K Buy
8,633
+344
+4% +$25K 0.36% 67
2022
Q2 		$631K Buy
8,289
+159
+2% +$12.1K 0.36% 66
2022
Q1 		$594K Buy
8,130
+3,240
+66% +$218K 0.33% 70
2021
Q4 		$305K Sell
4,890
-100
-2% -$5.87K 0.18% 126
2021
Q3 		$295K Buy
4,990
+110
+2% +$7.24K 0.19% 124
2021
Q2 		$326K Buy
4,880
+50
+1% +$3.26K 0.21% 109
2021
Q1 		$305K Buy
4,830
+500
+12% +$31.1K 0.22% 106
2020
Q4 		$293K Buy
4,330
+900
+26% +$55.3K 0.25% 98
2020
Q3 		$243K Sell
3,430
-1,500
-30% -$90.3K 0.25% 97
2020
Q2 		$290K Hold
4,930
– – 0.35% 75
2020
Q1 		$275K Sell
4,930
-500
-9% -$30.6K 0.43% 75
2019
Q4 		$349K Buy
+5,430
New +$311K 0.42% 83

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

&Partners's BMY Position: Q2 2026 in Review

&Partners increased its Bristol-Myers Squibb (BMY) stake by 2.2% in Q2 2026, buying an estimated $203K and bringing the position to 165,112 shares worth $9.51M. The position accounts for 0.04% of the portfolio, ranked #394.

&Partners first reported a position in BMY in Q4 2019 and has held it in 27 quarters since. The position peaked at $9.79M in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • &Partners held 165,112 shares of Bristol-Myers Squibb worth $9.51M as of Q2 2026.
  • &Partners bought 3,539 Bristol-Myers Squibb shares in Q2 2026, an estimated $203K.
  • Bristol-Myers Squibb made up 0.04% of &Partners's portfolio in Q2 2026, its #394 holding.
  • &Partners first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 27 quarters since.
  • &Partners's Bristol-Myers Squibb position peaked at $9.79M in Q1 2026.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.